Opinion/decision on a Paediatric investigation plan (PIP): Recarbrio, imipenem monohydrate,cilastatin sodium,relebactam (MK-7655A), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestat

Submitted by Anonymous (not verified) on 25 June 2025 - 10:35

Opinion/decision on a Paediatric investigation plan (PIP): Recarbrio, imipenem monohydrate,cilastatin sodium,relebactam (MK-7655A), decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestations, PIP number: P/0190/2024

Opinion/decision on a Paediatric investigation plan (PIP): Steglatro, Ertugliflozin, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Metabolism and nutrition disorders, PIP number: P/0189/2024

Submitted by Anonymous (not verified) on 25 June 2025 - 10:17

Opinion/decision on a Paediatric investigation plan (PIP): Steglatro, Ertugliflozin, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Metabolism and nutrition disorders, PIP number: P/0189/2024

Human medicines European public assessment report (EPAR): Foclivia, pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), Date of authorisation: 18/10/2009, Revision: 14, Status: Authorised

Submitted by Anonymous (not verified) on 25 June 2025 - 10:06

Human medicines European public assessment report (EPAR): Foclivia, pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted), Date of authorisation: 18/10/2009, Revision: 14, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness